Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / N••••••••

US B••••• L••••••••• Completes Strategic Investment in N••••••••

Add-on acquisitionclosedadd-onannounced Mar 9, 2026closed Mar 9, 2026Fact
What happened
Target
N••••••••
Platform
U• B••••• L••••••••• L••add-on basis: March 10, 2026 – P••• S••••• C•••••• portfolio company, US B••••• L••••••••• (“US B•••••”) announces that it has completed a strategic investment in N•••••••• (“N••••••••”), a provider of functional pathology services based in Melbourne, Australia.
Control
Control
Share acquired
unknown
Industry
healthcare / laborator
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
5 named
Buy side
  • D••• D•••••Deal partnerconfirmed
    “”This combination brings together complementary testing capabilities while expanding the platform’s international reach,” said D••• D•••••, Partner at P••• S••••• C••••••.”
  • U• B••••• L••••••••• L••Platformconfirmed
    “March 10, 2026 – P••• S••••• C•••••• portfolio company, US B••••• L••••••••• (“US B•••••”) announces that it has completed a strategic investment in N•••••••• (“N••••••••”), a provider of functional pathology services based in Melbourne, Australia.”
  • P••• S••••• C••••••Sponsorconfirmed
    “March 10, 2026 – P••• S••••• C•••••• portfolio company, US B••••• L••••••••• (“US B•••••”) announces that it has completed a strategic investment in N•••••••• (“N••••••••”), a provider of functional pathology services based in Melbourne, Australia.”
Side not stated
  • J••• F•••••••Managementconfirmed
    ““This acquisition marks an exciting new chapter for both US B••••• and N••••••••”, said J••• F•••••••, CEO of US B••••• L•••••••••.”
  • N••••••••Targetconfirmed
    “US B••••• L••••••••• Completes Strategic Investment in N••••••••”
Evidence
“US B••••• L••••••••• Completes Strategic Investment in N••••••••”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 18, 2026